Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
national blog main
boston blog main
boston top stories
deals
fda
national top stories
raleigh-durham blog main
san francisco blog main
clinical trials
new york blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
startups
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alexion pharmaceuticals
boston
bristol-myers squibb
celgene
drugs
hepatitis b
intercept pharmaceuticals
investing
What
disease
8
×
drug
8
×
medicines
bio
deal
gene
hepatitis
infectious
liver
pharma
pharmaceuticals
race
roundup
therapeutics
therapy
year
adds
advanced
alliance
alnylam’s
alternative
alzheimer's
approval
approved
areas
autoimmune
bacteria
bad
bff
biopharma
biosciences
bio’s
brain
brii
building
business
cancer
candidate
case
caught
Language
unset
Current search:
biotech
×
disease
×
drug
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed